Next Article in Journal
Electric Field Induced Fluorescence Modulation of Single Molecules in PMMA Based on Electron Transfer
Next Article in Special Issue
α-Tocopherol at Nanomolar Concentration Protects PC12 Cells from Hydrogen Peroxide-Induced Death and Modulates Protein Kinase Activities
Previous Article in Journal
Dual Targeting and Retrograde Translocation: Regulators of Plant Nuclear Gene Expression Can Be Sequestered by Plastids
Previous Article in Special Issue
Neuroprotective Effects of Erucin against 6-Hydroxydopamine-Induced Oxidative Damage in a Dopaminergic-like Neuroblastoma Cell Line
Int. J. Mol. Sci. 2012, 13(9), 11102-11129; doi:10.3390/ijms130911102

Erythropoietin: New Directions for the Nervous System

1,2,3,* , 1,3
1 Laboratory of Cellular and Molecular Signaling, Cancer Center, F 1220, New Jersey Health Sciences University, 205 South Orange Avenue, Newark, NJ 07101, USA 2 Cancer Institute of New Jersey, New Brunswick, New Jersey 08901, USA 3 New Jersey Health Sciences University, Newark, New Jersey 07101, USA
* Author to whom correspondence should be addressed.
Received: 11 July 2012 / Revised: 16 August 2012 / Accepted: 30 August 2012 / Published: 6 September 2012
(This article belongs to the Special Issue Neuroprotective Strategies 2012)
View Full-Text   |   Download PDF [279 KB, uploaded 19 June 2014]   |   Browse Figure


New treatment strategies with erythropoietin (EPO) offer exciting opportunities to prevent the onset and progression of neurodegenerative disorders that currently lack effective therapy and can progress to devastating disability in patients. EPO and its receptor are present in multiple systems of the body and can impact disease progression in the nervous, vascular, and immune systems that ultimately affect disorders such as Alzheimer’s disease, Parkinson’s disease, retinal injury, stroke, and demyelinating disease. EPO relies upon wingless signaling with Wnt1 and an intimate relationship with the pathways of phosphoinositide 3-kinase (PI 3-K), protein kinase B (Akt), and mammalian target of rapamycin (mTOR). Modulation of these pathways by EPO can govern the apoptotic cascade to control b-catenin, glycogen synthase kinase-3b, mitochondrial permeability, cytochrome c release, and caspase activation. Yet, EPO and each of these downstream pathways require precise biological modulation to avert complications associated with the vascular system, tumorigenesis, and progression of nervous system disorders. Further understanding of the intimate and complex relationship of EPO and the signaling pathways of Wnt, PI 3-K, Akt, and mTOR are critical for the effective clinical translation of these cell pathways into robust treatments for neurodegenerative disorders.
Keywords: Akt; Alzheimer’s disease; amyotrophic lateral sclerosis; apoptosis; cancer; erythropoietin; mTOR; oxidative stress; Parkinson’s disease; PI 3-K; Wnt Akt; Alzheimer’s disease; amyotrophic lateral sclerosis; apoptosis; cancer; erythropoietin; mTOR; oxidative stress; Parkinson’s disease; PI 3-K; Wnt
This is an open access article distributed under the Creative Commons Attribution License (CC BY) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
MDPI and ACS Style

Maiese, K.; Chong, Z.Z.; Shang, Y.C.; Wang, S. Erythropoietin: New Directions for the Nervous System. Int. J. Mol. Sci. 2012, 13, 11102-11129.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


Cited By

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert